ERBB2 and gastric cancer: In this presentation, we found that a patient with metastatic GC who received trastuzumab plus synchronous chemotherapy successfully resected the main tumor site had variations in HER2 status during treatment, demonstrating that temporal heterogeneity resulted in HER2-negative subclones gaining a growth advantage, leading to recurrence and metastasis.